Cargando…
A three‐lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
BACKGROUND: Current strategies are insufficient to predict pathologically complete response (pCR) for esophageal squamous cell carcinomas (ESCCs) before treatment. Here, we aim to develop a novel long noncoding RNA (lncRNA) signature for pCR and outcome prediction of ESCCs through a multicenter anal...
Autores principales: | Zhang, Chaoqi, Zhang, Zhihui, Zhang, Guochao, Xue, Liyan, Yang, Haijun, Luo, Yuejun, Zheng, Xiaoli, Zhang, Yonglei, Yuan, Yufen, Lei, Ruixue, Yang, Zhaoyang, Zheng, Bo, Zhang, Zhen, Wang, Le, Che, Yun, Wang, Sihui, Wang, Feng, Fang, Lingling, Zeng, Qingpeng, Li, Jiagen, Gao, Shugeng, Xue, Qi, Sun, Nan, He, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448795/ https://www.ncbi.nlm.nih.gov/pubmed/32898328 http://dx.doi.org/10.1002/ctm2.156 |
Ejemplares similares
-
An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020) -
m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021) -
The landscape of m(6)A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance
por: Zhang, Chaoqi, et al.
Publicado: (2021) -
Tumor‐infiltrating CD8(+) T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited‐stage small cell esophageal carcinoma
por: Zhang, Zhihui, et al.
Publicado: (2021) -
Comprehensive analyses of N
(6)‐methyladenosine‐related long noncoding RNA profiles with prognosis, chemotherapy response, and immune landscape in small cell lung cancer
por: Luo, Yuejun, et al.
Publicado: (2022)